Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2022
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Muscarinic Acetylcholine Receptor M1 Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Muscarinic Acetylcholine Receptor M1 Antagonists: Overview
The mAChRs are a sub-class of the G-protein-coupled receptors (GPCRs) family, comprising 5 subtypes (M1-M5). M1, M3, and M5 are coupled with the Gq protein and, via phospholipase C signaling pathway, generate cytosolic calcium transients; M2 and M4, on the other hand, couple with the Gi protein inhibiting the adenylyl cyclase. While obtaining mAChRs subtype-selective ligands is a primary goal in drug development previous attempts have failed due to the highly conserved structure of the orthosteric binding site across the muscarinic receptor family members.
Muscarinic Acetylcholine Receptor M1 Antagonists Emerging Drugs Chapters
This segment of the Muscarinic Acetylcholine Receptor M1 Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Muscarinic Acetylcholine Receptor M1 Antagonists Emerging Drugs
Further product details are provided in the report……..
Muscarinic Acetylcholine Receptor M1 Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Muscarinic Acetylcholine Receptor M1 Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Muscarinic Acetylcholine Receptor M1 Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscarinic Acetylcholine Receptor M1 Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscarinic Acetylcholine Receptor M1 Antagonists drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Muscarinic Acetylcholine Receptor M1 Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Muscarinic Acetylcholine Receptor M1 Antagonists: Overview
The mAChRs are a sub-class of the G-protein-coupled receptors (GPCRs) family, comprising 5 subtypes (M1-M5). M1, M3, and M5 are coupled with the Gq protein and, via phospholipase C signaling pathway, generate cytosolic calcium transients; M2 and M4, on the other hand, couple with the Gi protein inhibiting the adenylyl cyclase. While obtaining mAChRs subtype-selective ligands is a primary goal in drug development previous attempts have failed due to the highly conserved structure of the orthosteric binding site across the muscarinic receptor family members.
Muscarinic Acetylcholine Receptor M1 Antagonists Emerging Drugs Chapters
This segment of the Muscarinic Acetylcholine Receptor M1 Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Muscarinic Acetylcholine Receptor M1 Antagonists Emerging Drugs
- KarXT - Karuna Therapeutics
Further product details are provided in the report……..
Muscarinic Acetylcholine Receptor M1 Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Muscarinic Acetylcholine Receptor M1 Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Muscarinic Acetylcholine Receptor M1 Antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Muscarinic Acetylcholine Receptor M1 Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscarinic Acetylcholine Receptor M1 Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscarinic Acetylcholine Receptor M1 Antagonists drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Muscarinic Acetylcholine Receptor M1 Antagonists R&D. The therapies under development are focused on novel approaches for Muscarinic Acetylcholine Receptor M1 Antagonists.
- Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Muscarinic Acetylcholine Receptor M1 Antagonists drugs?
- How many Muscarinic Acetylcholine Receptor M1 Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Muscarinic Acetylcholine Receptor M1 Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Muscarinic Acetylcholine Receptor M1 Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Muscarinic Acetylcholine Receptor M1 Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Karuna Therapeutics
- KarXT
Introduction
Executive Summary
Muscarinic Acetylcholine Receptor M1 Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Muscarinic Acetylcholine Receptor M1 Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Muscarinic Acetylcholine Receptor M1 Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Muscarinic Acetylcholine Receptor M1 Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
KarXT - Karuna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Muscarinic Acetylcholine Receptor M1 Antagonists Key Companies
Muscarinic Acetylcholine Receptor M1 Antagonists Key Products
Muscarinic Acetylcholine Receptor M1 Antagonists- Unmet Needs
Muscarinic Acetylcholine Receptor M1 Antagonists- Market Drivers and Barriers
Muscarinic Acetylcholine Receptor M1 Antagonists- Future Perspectives and Conclusion
Muscarinic Acetylcholine Receptor M1 Antagonists Analyst Views
Muscarinic Acetylcholine Receptor M1 Antagonists Key Companies
Appendix
Executive Summary
Muscarinic Acetylcholine Receptor M1 Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Muscarinic Acetylcholine Receptor M1 Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Muscarinic Acetylcholine Receptor M1 Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Muscarinic Acetylcholine Receptor M1 Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
KarXT - Karuna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Muscarinic Acetylcholine Receptor M1 Antagonists Key Companies
Muscarinic Acetylcholine Receptor M1 Antagonists Key Products
Muscarinic Acetylcholine Receptor M1 Antagonists- Unmet Needs
Muscarinic Acetylcholine Receptor M1 Antagonists- Market Drivers and Barriers
Muscarinic Acetylcholine Receptor M1 Antagonists- Future Perspectives and Conclusion
Muscarinic Acetylcholine Receptor M1 Antagonists Analyst Views
Muscarinic Acetylcholine Receptor M1 Antagonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Muscarinic Acetylcholine Receptor M1 Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Muscarinic Acetylcholine Receptor M1 Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Muscarinic Acetylcholine Receptor M1 Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Muscarinic Acetylcholine Receptor M1 Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
